TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Corporate presentation and live webcast scheduled for
A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff141/tffp/1846800. Following the conference, an archived version of the webcast will be available under the Events Calendar tab in the Investors section of the Company's website.
About TFF Pharmaceuticals’ Thin Film Freezing technology platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology. allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005631/en/
Company Contacts:
President and CEO
gmattes@tffpharma.com
737-802-1973
Chief Financial Officer
kcoleman@tffpharma.com
817-989-6358
Investor Relations and Media Contact:
LaVoieHealthScience
psagan@lavoiehealthscience.com
617-953-4779
Source: